Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$776.47

0.04 (0.01%)

, GOOGL

Alphabet Class A

$801.23

-1.56 (-0.19%)

15:17
10/06/16
10/06
15:17
10/06/16
15:17

Alphabet's Verily steps into Zika market with mosquito sterilization project

Alphabet's health and life science subsidiary Verily announced the "Debug Project," an initiative aimed at reducing mosquito-spread diseases through a new, more automated approach to mosquito sterilization technology. "Towards the end of 2014, some of us at Google started exploring what we could do to help solve the mosquito problem... We talked with experts from around the world working on many different approaches. One stood out to us: the the sterile insect technique... We decided to focus on the problem of reducing that cost [of sterilization technologies] with automation. We're using Verily's combination of data analytics, sensors, lab automation technology, and scientific expertise to solve specific issues around mass-production and sex-sorting of mosquitoes, and to enable efficient and targeted releases. We also decided to focus on one particular mosquito: Aedes aegypti. While there are thousands of different species of mosquito, Aedes aegypti is the primary vector of dengue, Zika, chikungunya and yellow fever, and there aren't good ways to control this mosquito. The Debug Project is still early... We have promising prototypes of our automated rearing, sex separation, and release systems along with new designs for sensors and traps to measure mosquito populations. We're announcing Debug today because we'll soon be ready to try these outside of our lab," the company said. Publicly traded companies in the Zika space include Sanofi (SNY), GlaxoSmithKline (GSK), Intrexon (XON), Inovio (INO), Cerus (CERS), Chembio Diagnostics (CEMI), and NewLink Genetics (NLNK). Reference Link

GOOG

Alphabet

$776.47

0.04 (0.01%)

GOOGL

Alphabet Class A

$801.23

-1.56 (-0.19%)

SNY

Sanofi

$38.52

-0.04 (-0.10%)

GSK

GlaxoSmithKline

$42.88

-0.452 (-1.04%)

XON

Intrexon

$28.78

-0.13 (-0.45%)

INO

Inovio

$9.43

0.03 (0.32%)

CERS

Cerus

$6.26

0.06 (0.97%)

CEMI

Chembio Diagnostics

$7.33

-0.05 (-0.68%)

NLNK

NewLink Genetics

$15.73

1.04 (7.08%)

  • 07

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

  • 10

    Nov

  • 15

    Nov

  • 15

    Jan

  • 29

    Mar

GOOG Alphabet
$776.47

0.04 (0.01%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
GOOGL Alphabet Class A
$801.23

-1.56 (-0.19%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
SNY Sanofi
$38.52

-0.04 (-0.10%)

09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Neutral
Sanofi upgraded to Neutral from Underperform at Exane BNP Paribas
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Sanofi initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Sanofi with a Neutral rating and EUR 76 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
GSK GlaxoSmithKline
$42.88

-0.452 (-1.04%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
XON Intrexon
$28.78

-0.13 (-0.45%)

05/11/16
STFL
05/11/16
NO CHANGE
Target $57
STFL
Buy
Intrexon appears to be making incremental progress, says Stifel
Stifel analyst Thomas Shrader acknowledges that Intrexon's Q1 results press release and associated call were "highly complex" and the stock remains "highly polarizing," but he believes the company is making incremental progress, that the potential deployment of its mosquitoes to combat Zika seems to be advancing, and noted that its gas to liquid bioconversion programs were reported to be in the "red zone" of development. The company appears to be increasingly focused on non-therapeutic and non-medical projects and Shrader continues to view its gas to liquid energy conversion program as the highest value opportunity at Intrexon, he told investors in a post-earnings research note. The firm keeps a Buy rating and $57 price target on Intrexon shares.
09/08/16
JMPS
09/08/16
NO CHANGE
JMPS
Intrexon could benefit from Zika eradication efforts, says JMP Securities
JMP Securities analyst Jason Butler notes that a bipartisan group of Florida House members and the leaders of the state's Pinellas County asked the federal government to grant a waiver that would allow the use of Intrexon's Friendly Aedes for Zika eradication efforts. The analyst says that a waiver could result in "nearer term government orders." He keeps a $42 price target and Outperform rating on Intrexon.
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
05/03/16
05/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wal-Mart (WMT) initiated with an Underperform at RBC Capital due to a negative risk/reward ratio, citing the company's massive size, intensifying competition and the shift towards e-commerce. 2. Costco (COST) initiated with an Outperform at RBC Capital with the firm saying that the company's membership fees provide it with "a growing, high margin revenue stream," while it has " some of the best/most consistent customer traffic growth in all of retail." 3. Kroger (KR) initiated with a Neutral at SunTrust. 4. H&R Block (HRB) initiated with a Neutral at Sterne Agee CRT. 5. Intrexon (XON) initiated with an Outperform at JMP Securities by analyst Jason Butler, who said Intrexon has a "highly scalable" business model and has achieved technological and regulatory validation in the areas of food, health, and the environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
INO Inovio
$9.43

0.03 (0.32%)

01/22/16
MAXM
01/22/16
NO CHANGE
MAXM
Inovio mentioned positively at Maxim
08/09/16
MAXM
08/09/16
DOWNGRADE
MAXM
Hold
Inovio downgraded to Hold from Buy at Maxim
02/19/16
PIPR
02/19/16
NO CHANGE
Target $31
PIPR
Overweight
Piper highlights Inovio amid spread of Zika
Piper Jaffray analyst Charles Duncan highlights Inovio Pharmaceuticals as the Zika virus spreads, calling the company a leader among potential vaccine players. The company's SynCon technology has a "higher than usual probability of clinical success" in Zika given its experience with other flaviviruses and tropical diseases, Duncan tells investors in a research note. He has an Overweight rating on Inovio with a $31 price target. The stock closed yesterday down 47c to $6.45.
10/04/16
BMUR
10/04/16
INITIATION
Target $18
BMUR
Buy
Inovio assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Inovio Pharmaceuticals with a Buy rating and $18 price target.
CERS Cerus
$6.26

0.06 (0.97%)

08/29/16
CANT
08/29/16
NO CHANGE
CANT
Cerus should be bought at current levels, says Cantor
Cantor analyst Bryan Brokmeier recommends that investors buy Cerus' stock after the FDA recommended that all U.S. blodd centers implement either blood testing for the Zika Virus or FDA-approved pathogen-reduction technology. The analyst says that Cerus is the sole provider of the latter technology. He keeps a $9 price target and Buy rating on the shares.
08/26/16
CANT
08/26/16
NO CHANGE
Target $9
CANT
Buy
Cantor says buy Cerus following FDA industry guidance
Cantor analyst Bryan Brokmeier says investors should buy shares of Cerus following the FDA's revised industry guidance recommending all blood centers across the U.S. implement either blood testing for the Zika Virus or FDA approved pathogen-reduction technology, of which the company has the only available technology. Further, the analyst believes this is a "big step" toward accelerated adoption of Cerus' INTERCEPT platform. Brokmeier reiterates a Buy rating and $9 price target on the shares.
08/05/16
CANT
08/05/16
NO CHANGE
CANT
Cerus should be bought after results, says Cantor
Cantor analyst Bryan Brokmeier recommends buying Cerus stock after the company reported Q2 results that he calls "solid." The analyst says that the company's regulatory program for red cells is on track. He keeps a $9 price target and Buy rating on the shares.
08/03/16
CANT
08/03/16
NO CHANGE
Target $9
CANT
Buy
Cantor sees Zika headlines as catalyst for Cerus shares
Cantor Fitzgerald analyst Bryan Brokmeier recommends buying shares of Cerus ahead of tomorrow's Q2 earnings report. The analyst believes the growing awareness and fear of Zika, especially during the Olympics, which start on August 5, may drive shares of companies that are involved in combating Zika higher. He reminds investors that Cerus offers the only FDA approved pathogen inactivation technology and was recently included in the agency's guidance document for reducing the risk of transfusion-transmission of Zika. The greatest opportunity for Cerus is on the Gulf Coast, which provides $29.7M and $26.2M of revenue opportunities for platelet and plasma, respectively, Brokmeier tells investors in an intraday research note. He keeps a Buy rating on the shares with a $9 price target.
CEMI Chembio Diagnostics
$7.33

-0.05 (-0.68%)

08/02/16
CHLM
08/02/16
NO CHANGE
Target $10
CHLM
Buy
Chembio could double revenue based on Zika opportunity, says Craig-Hallum
Craig-Hallum analyst Bill Bonello believes Chembio Diagnostics shares can double over the next two years as the $1.5B rapid test market shifts from traditional technology to Chembio's proprietary DPP technology, adding that he think's Chembio could double revenue based on the Zika opportunity alone. The DPP technology is on the market today for detection of STD's, but that opportunity is "dwarfed by fever illness," Bonello tells investors. The firm reiterates its Buy rating and $10 price target on Chembio shares.
11/04/15
11/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allegiance Bancshares (ABTX) initiated with a Market Perform at Keefe Bruyette... BioDelivery Sciences (BDSI) initiated with a Buy at Cantor... Cabela's (CAB) initiated with an Overweight at Barclays... Cara Therapeutics (CARA) initiated with a Buy at Cantor... Chembio Diagnostics (CEMI) initiated with a Speculative Buy at Benchmark... Depomed (DEPO) initiated with a Buy at Cantor... Dick's Sporting (DKS) initiated with an Equal Weight at Barclays... Egalet (EGLT) initiated with a Buy at Cantor... Flexion (FLXN) initiated with a Buy at Cantor... HP Enterprise (HPE) initiated with a Buy at UBS... HP Inc. (HPQ) initiated with a Neutral at UBS... Opexa Therapeutics (OPXA) initiated with a Buy at Chardan... Smith & Nephew (SNN) initiated with a Neutral at Sterne Agee CRT... Stryker (SYK) initiated with a Neutral at Sterne Agee CRT... The Medicines Co. (MDCO) initiated with a Buy at Chardan... Tonix Pharmaceuticals (TNXP) initiated with a Buy at Cantor... Vail Resorts (MTN) initiated with a Buy at Janney Capital... Wright Medical (WMGI) initiated with a Buy at Sterne Agee CRT... Zimmer Biomet (ZBH) initiated with a Buy at Sterne Agee CRT.
11/04/15
BNCH
11/04/15
INITIATION
Target $6
BNCH
Speculative Buy
Chembio Diagnostics initiated with a Speculative Buy at Benchmark
Target $6.
NLNK NewLink Genetics
$15.73

1.04 (7.08%)

05/10/16
RHCO
05/10/16
DOWNGRADE
RHCO
Neutral
NewLink Genetics downgraded to Neutral from Buy at SunTrust
05/10/16
CANT
05/10/16
NO CHANGE
Target $20
CANT
Buy
NewLink Genetics price target lowered to $20 from $62 at Cantor
Cantor Fitzgerald analyst Mara Goldstein noted that NewLink Genetics' IMPRESS trial failed to meet its OS endpoint and said the results suggest little chance of a salvageable outcome, but thinks that the company's IDO platform can be "an important valuation backstop" for the shares and is well discounted after the post-failure pullback. Goldstein cut her price target on NewLink to $20 from $62, but maintains a Buy rating on the stock, citing the potential for the IDO platform as well as the company's Ebola vaccine.
03/22/16
BARD
03/22/16
INITIATION
Target $27
BARD
Outperform
NewLink Genetics initiated with an Outperform at Baird
Target $27.
03/22/16
BARD
03/22/16
INITIATION
Target $27
BARD
Outperform
NewLink Genetics initiated with an Outperform at Baird
Target $27.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

, NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Options
Two new option listings and three option delistings on December 9th »

New option listings for…

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

LGF

Lionsgate

$26.09

1.1 (4.40%)

LNKD

LinkedIn

STRZA

Starz

$35.52

0.59 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$12.33

-0.3 (-2.38%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Conference/Events
Pure Storage participates in a conference call with UBS »

UBS IT Hardware & EMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

08:30
12/09/16
12/09
08:30
12/09/16
08:30
General news
U.S. equities are back in the green »

U.S. equities are back in…

SGYP

Synergy Pharmaceuticals

$5.54

0.06 (1.09%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Hot Stocks
Breaking Hot Stocks news story on Synergy Pharmaceuticals »

Synergy Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

LFUS

Littelfuse

$154.58

3.1 (2.05%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Littelfuse to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WWD

Woodward

$70.84

-0.26 (-0.37%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Wayfair Woodward to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DVAX

Dynavax

$4.80

-0.2 (-4.00%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Dynavax to host research and development day »

Cancer Research and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 15

    Dec

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Downgrade
Duluth Holdings rating change  »

Duluth Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBAI

Lakeland Bancorp

$19.15

0.3 (1.59%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Syndicate
Breaking Syndicate news story on Lakeland Bancorp »

Lakeland Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$11.53

-2.9 (-20.10%)

08:23
12/09/16
12/09
08:23
12/09/16
08:23
Syndicate
Clearside Biomedical 4M share Secondary priced at $9.00 »

JPMorgan, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BIIB

Biogen

$289.54

4.24 (1.49%)

, LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

08:21
12/09/16
12/09
08:21
12/09/16
08:21
Recommendations
Biogen, Eli Lilly analyst commentary  »

Biogen has positive read…

BIIB

Biogen

$289.54

4.24 (1.49%)

LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

08:20
12/09/16
12/09
08:20
12/09/16
08:20
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

FNSR

Finisar

$34.13

1.89 (5.86%)

08:17
12/09/16
12/09
08:17
12/09/16
08:17
Recommendations
Finisar analyst commentary  »

Finisar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$83.39

0.47 (0.57%)

08:15
12/09/16
12/09
08:15
12/09/16
08:15
Recommendations
Zebra Technologies analyst commentary  »

Zebra Technologies prie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$170.71

2.16 (1.28%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Recommendations
Broadcom analyst commentary  »

Broadcom poised for above…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

, MYL

Mylan

$36.06

1.56 (4.52%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Periodicals
UCB Pharma Vimpat patent 'thrown out' by patent office, Bronte Capital reports »

Argentum…

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

MYL

Mylan

$36.06

1.56 (4.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HLT

Hilton

$26.24

-0.8 (-2.96%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Downgrade
Hilton rating change  »

Hilton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CDEV

Centennial Resource Development

$18.29

-0.32 (-1.72%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Initiation
Centennial Resource Development initiated  »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTEA

Long Island Iced Tea

$4.91

0.2 (4.25%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Hot Stocks
Long Island Iced Tea agrees to acquire ALO Juice »

Long Island Iced Tea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCON

Superconductor Technologies

$2.02

-0.13 (-6.05%)

08:11
12/09/16
12/09
08:11
12/09/16
08:11
Syndicate
Superconductor Technologies raises $10.2M in a public offering »

The offering was priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMG

Cellular Biomedicine

$13.35

0.1 (0.75%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Hot Stocks
Cellular Biomedicine announces 3-month interim safety data from AlloJoin trial »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$89.30

5.57 (6.65%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIRG

Airgain

$18.62

-2.13 (-10.27%)

08:08
12/09/16
12/09
08:08
12/09/16
08:08
Syndicate
Airgain 2.35M share Secondary priced at $17.00 »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

SMBK

SmartBank

$19.96

0.66 (3.42%)

, ACBI

Atlantic Capital

$17.00

0.5 (3.03%)

08:08
12/09/16
12/09
08:08
12/09/16
08:08
Hot Stocks
SmartBank to acquire branch office and assets of FSG Bank from Atlantic Capital »

SmartFinancial (SMBK),…

SMBK

SmartBank

$19.96

0.66 (3.42%)

ACBI

Atlantic Capital

$17.00

0.5 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

08:07
12/09/16
12/09
08:07
12/09/16
08:07
Conference/Events
Wells Fargo holds a conference call »

CFO Shrewsberry and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.